Genetic and Chromosomal Screening | Types, Procedure & Cost Guide

Genetic and Chromosomal Screening | Types, Procedure & Cost Guide

Genetic and Chromosomal Screening encompasses a spectrum of non-invasive prenatal tests, carrier screens, and diagnostic evaluations designed to assess a fetus’s risk for inherited gene mutations or chromosomal variations. These evaluations provide parents and clinicians with early, clear insights into fetal health, aiding informed care planning and birth management.

Whether evaluating risk for common trisomies (such as Down syndrome) or screening parents prior to conception for recessive gene mutations, modern genetic testing blends maternal blood analysis, ultrasound metrics, and advanced cell-free fetal DNA (cfDNA) technology.

Core Categories of Genetic and Chromosomal Testing

Prenatal genetic evaluation is broadly divided into two primary distinct methodologies: Screening Tests (which estimate statistical risk without altering the pregnancy) and Diagnostic Tests (which provide definitive diagnostic confirmation).

                    [Genetic and Chromosomal Testing Framework]
                                         │
     ┌───────────────────────────────────┴───────────────────────────────────┐
     ▼                                                                       ▼
[Screening Tests]                                                   [Diagnostic Tests]
 • Non-Invasive Prenatal Testing (NIPT/cfDNA)                        • Chorionic Villus Sampling (CVS)
 • First Trimester Combined Screening (NT + Double Marker)           • Amniocentesis
 • Second Trimester Quadruple Marker Screen                          • Karyotyping & Chromosomal Microarray
 • Extended Carrier Screening (Parents)

Non-Invasive vs. Invasive Testing Options

Test Name	Typical Timing	Method	What It Evaluates	Accuracy / Reliability
Combined First-Trimester Screen	Weeks 11 – 13	Ultrasound (NT scan) + Maternal Blood (hCG, PAPP-A)	Risk estimate for Trisomy 21, 18, 13 and structural defects	~85% – 90% Detection Rate
Non-Invasive Prenatal Testing (NIPT)	Week 10+	Maternal Blood Draw (Cell-Free Fetal DNA)	Trisomies 21, 18, 13, sex chromosome aneuploidies, microdeletions	>99% for Down Syndrome
Quadruple Marker Screen	Weeks 15 – 22	Maternal Blood Draw (AFP, hCG, Estriol, Inhibin-A)	Neural tube defects (spina bifida) and trisomy risk	~81% – 85% Detection Rate
Chorionic Villus Sampling (CVS)	Weeks 11 – 13	Placental tissue biopsy (Transabdominal / Transvaginal)	Definitive diagnostic karyotype & array analysis	>99.5% Diagnostic Accuracy
Amniocentesis	Weeks 15 – 20	Amniotic fluid aspiration (Ultrasound-guided needle)	Definitive diagnostic karyotype & full genetic panels	>99.5% Diagnostic Accuracy

Clinical Screening and Diagnostic Pathway

1.1. Carrier Screening & NIPT Selection:Pre-Conception / Early Week 10.

Parents assess family medical history and elect for Extended Carrier Screening or Non-Invasive Prenatal Testing (NIPT) from 10 weeks onward using a standard maternal blood draw.

2.2. First-Trimester Ultrasound & Biomarkers:Weeks 11–13.

A certified sonographer performs a Nuchal Translucency (NT) ultrasound scan to measure the fluid space at the back of the baby’s neck, alongside serum biochemistry markers.

3.3. Results & Genetic Counseling:Risk Assessment.

Clinicians analyze laboratory and ultrasound data. If a screening result returns a high-risk probability, parents meet with a genetic counselor to interpret the statistical risk.

4.4. Diagnostic Confirmation:Weeks 11–20 (If Required).

If confirmed high-risk or if structural abnormalities appear on ultrasound, invasive diagnostic testing (CVS or Amniocentesis) is offered to obtain definitive genetic confirmation.

Indicative Cost Estimates for Screening

Genetic testing costs vary based on geographical region, coverage scope, and laboratory complexity:

• First Trimester Double Marker + NT Scan: ₹2,500 – ₹5,000
• Basic NIPT (Trisomies 21, 18, 13): ₹12,000 – ₹18,000
• Comprehensive Expanded NIPT (Includes Microdeletions & Sex Chromosomes): ₹20,000 – ₹30,000
• Diagnostic Amniocentesis / CVS Procedure & Karyotyping: ₹15,000 – ₹35,000

Frequently Asked Questions (FAQs)

1. What is the main difference between screening and diagnostic genetic tests?

Screening tests (such as NIPT or Double Marker blood tests) estimate the probability or risk that a fetus has a genetic condition without touching the pregnancy directly. Diagnostic tests (such as Amniocentesis or CVS) analyze actual placental cells or amniotic fluid to give a definitive yes-or-no answer.

2. Can NIPT diagnose Down syndrome with 100% certainty?

While NIPT is extraordinarily accurate (detecting over 99% of Down syndrome cases), it is still classified as a screening test. High-risk NIPT results should always be confirmed via diagnostic amniocentesis or CVS before making major clinical management decisions.

3. Are non-invasive genetic screening tests safe for the baby?

Yes. Non-invasive screenings like NIPT and maternal serum marker tests require only a standard blood draw from the mother’s arm, posing zero risk of miscarriage or physical harm to the fetus.

4. Who should consider genetic and chromosomal screening during pregnancy?

Genetic screening is offered to all pregnant individuals regardless of age. However, it is strongly advised for women aged 35 or older at delivery, couples with a family history of genetic conditions, individuals with previous pregnancy complications, or cases where an routine ultrasound shows unusual physical findings.

5. What conditions are screened during a standard prenatal genetic panel?

Standard panels screen for common trisomies: Trisomy 21 (Down syndrome), Trisomy 18 (Edwards syndrome), and Trisomy 13 (Patau syndrome), as well as sex chromosome variations (such as Turner syndrome and Klinefelter syndrome). Extended panels can also look for microdeletions.